Link to the University of Pittsburgh Homepage
Link to the University Library System Homepage Link to the Contact Us Form

ERCC1 and XRCC1 as biomarkers for lung and head and neck cancer

Vaezi, A and Feldman, CH and Niedernhofer, LJ (2011) ERCC1 and XRCC1 as biomarkers for lung and head and neck cancer. Pharmacogenomics and Personalized Medicine, 4 (1). 47 - 63.

Available under License : See the attached license file.

Download (687kB) | Preview
[img] Plain Text (licence)
Available under License : See the attached license file.

Download (1kB)


Advanced stage non-small cell lung cancer and head and neck squamous cell carcinoma are both treated with DNA damaging agents including platinum-based compounds and radiation therapy. However, at least one quarter of all tumors are resistant or refractory to these genotoxic agents. Yet the agents are extremely toxic, leading to undesirable side effects with potentially no benefit. Alternative therapies exist, but currently there are no tools to predict whether the first-line genotoxic agents will work in any given patient. To maximize therapeutic success and limit unnecessary toxicity, emerging clinical trials aim to inform personalized treatments tailored to the biology of individual tumors. Worldwide, significant resources have been invested in identifying biomarkers for guiding the treatment of lung and head and neck cancer. DNA repair proteins of the nucleotide excision repair pathway (ERCC1) and of the base excision repair pathway (XRCC1), which are instrumental in clearing DNA damage caused by platinum drugs and radiation, have been extensively studied as potential biomarkers of clinical outcomes in lung and head and neck cancers. The results are complex and contradictory. Here we summarize the current status of single nucleotide polymorphisms, mRNA, and protein expression of ERCC1 and XRCC1 in relation to cancer risk and patient outcomes. © 2011 Vaezi et al, publisher and licensee Dove Medical Press Ltd.


Social Networking:
Share |


Item Type: Article
Status: Published
CreatorsEmailPitt UsernameORCID
Vaezi, A
Feldman, CH
Niedernhofer, LJniedernh@pitt.eduNIEDERNH
Centers: Other Centers, Institutes, Offices, or Units > Hillman Cancer Center
Date: 22 December 2011
Date Type: Publication
Journal or Publication Title: Pharmacogenomics and Personalized Medicine
Volume: 4
Number: 1
Page Range: 47 - 63
Schools and Programs: School of Medicine > Microbiology and Molecular Genetics
School of Medicine > Otolaryngology
Refereed: Yes
Article Type: Review
Date Deposited: 04 Dec 2012 22:36
Last Modified: 03 Feb 2019 06:55


Monthly Views for the past 3 years

Plum Analytics

Actions (login required)

View Item View Item